ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Outcomes Among Racial and Ethnic Minority Patients With Advanced Cancers in Phase 1 Trials: A Meta-Analysis.JAMA network open · 2024Pooled it
- The role of age on dose-limiting toxicities in phase I dose-escalation trials.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Pooled it
- Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.Gynecologic oncology · 2016Trial
- Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.The oncologist · 2026Article
- Evaluation of six clinical prognostic scores in NSCLC patients undergoing first line chemoimmunotherapy.Frontiers in immunology · 2026Article
- Observational
- Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER.JNCI cancer spectrum · 2025Article
- A Real-World Evaluation of Clinical Prognostic Scores in Advanced Melanoma Treated with Immune Checkpoint Inhibitors.Journal of clinical medicine · 2025Article
- The prognostic value of a laboratory cachexia score (LCAS) defined by LDH, CRP and albumin in patients with advanced lung cancer.BMC cancer · 2025Article
- Impact of travel costs on disparities in precision oncology clinical trials.ESMO real world data and digital oncology · 2025Article
- Prognostic value of the MDACC-NLR score in extensive-stage small-cell lung cancer treated with first-line chemoimmunotherapy.Frontiers in immunology · 2025Article
- Review
- Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram.Frontiers in immunology · 2024Article
- Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials.Journal of gastrointestinal cancer · 2023Article
- Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital.JAMA network open · 2023Article
- Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials.British journal of cancer · 2023Article
- Comparison of Four Clinical Prognostic Scores in Patients with Advanced Gastric and Esophageal Cancer.The oncologist · 2023Article
- Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.Journal of immunotherapy and precision oncology · 2023Article
- Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.Scientific reports · 2022Review
- Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.Clinical genitourinary cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo determine whether the Royal Marsden Hospital (RMH; London, UK) prognostic score for phase I patients can be validated in a large group of individuals seen in a different center and whether other prognostic variables are also relevant, we present an analysis of 1,181 patients treated in the MD Anderson Cancer Center (MDACC; Houston, TX) phase I clinic. EXPERIMENTAL
designMedical records of 1,181 consecutive patients who were treated on at least one trial in the phase I clinic were reviewed.
resultsThe median age was 58 years and 50% were women. The median number of prior therapies was four and median survival 10 months [95% confidence interval (CI), 9.1-10.9 months]. Independent factors that predicted shorter survival in a multivariate Cox model and could be internally validated included RMH score of >1 (P < 0.0001; albumin <3.5 g/dL; lactate dehydrogenase >upper limit of normal, and >two sites of metastases), gastrointestinal tumor type (P < 0.0001), and Eastern Cooperative Oncology Group performance status ≥ 1 (P = 0.0004). The median survival was 24.0, 15.2, 8.4, 6.2, and 4.1 months for patients with 0, 1, 2, 3, and 4 or 5 of the above risk factors, respectively.
conclusionThe RMH score was validated in a large group of patients at MDACC. Internal validation of the independent prognostic factors for survival led to the development of the MDACC prognostic score, a modification of the RMH score that strengthens it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.